Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that topical calcipotriol did not significantly enhance hair growth when combined with SADBE in patients with severe alopecia areata.

This article reviews the multifaceted approach required for acne vulgaris treatment, emphasizing individualized combination therapies tailored to clinical severity and patient psychological profiles, but no new results are included.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

This case study reported significant clinical improvement in a 26-year-old male with dissecting cellulitis of the scalp after treatment with upadacitinib, suggesting that JAK inhibitors may be a promising option for refractory cases, where standard treatments have limited success.

This study observed that early treatment with ritlecitinib in patients with alopecia areata, especially when severity is low, led to more favorable responses, and continued improvement was seen up to 24 months, offering guidance on treatment timing and duration.

In this case study, treatment with the selective JAK1 inhibitor upadacitinib significantly improved symptoms in a patient with refractory alopecia areata, vitiligo, ankylosing spondylitis, and allergic asthma-nasal syndrome, though a transient liver function abnormality was noted.

In this survey of dermatologists, pimozide was most commonly identified as the preferred first-line antipsychotic for treating delusions of parasitosis, followed by risperidone.

This case report from the provided study details a previously unreported adverse effect of salivary gland inflammation potentially linked to acitretin therapy for generalized pustular psoriasis, suggesting further research is needed to explore this association.

This phase 1 study reported that after administering supratherapeutic doses of cortexolone 17α‐propionate, a topical antiandrogen intended for hair loss treatment, there was no effect on the QTc interval, indicating no measurable cardiac safety concerns in the concentration range tested.

In this phase 3 trial analysis, baricitinib improved scalp hair growth in adults with severe alopecia areata, with a faster and higher response in those receiving 4 mg compared to 2 mg, but response varied with severity at baseline and continued through week 52.

This article highlights disparities in the prevalence of alopecia areata among people with skin of color and suggests this information could help dermatologic providers address challenges in treating this population.

In this study, researchers found that among adults with severe alopecia, continued treatment with baricitinib for 104 weeks maintained hair regrowth effectively in those who responded at 52 weeks, with improved outcomes noted in some initially non-responders receiving 4 mg.

This review discusses the applications of the 308-nm excimer laser in treating various dermatologic conditions and suggests treatment is generally well tolerated, but calls for larger long-term studies.

This abstract lists numerous dermatological side effects and reactions associated with various medications but reports no new research findings.

This study found that a synthetic avicequinone C analogue, 5e, was significantly more potent in inhibiting steroid 5α-reductase type 1 activity in human keratinocytes compared to the original isolated compound.

This article provides an overview of acne vulgaris, discussing its causes, presentation, and psychosocial impact, but it reports no new research findings or clinical results.

This integrative literature review found that hydroxychloroquine may stabilize inflammatory scarring autoimmune alopecias like frontal fibrosing alopecia, especially when combined with other therapies, while its effectiveness in non-scarring alopecias appears inconsistent and is limited to refractory cases.

In this case study, combination therapy with dapsone and isotretinoin significantly improved perifolliculitis capitis abscedens et suffodiens, with the patient remaining symptom-free for six months on reduced medication.

This study found that calcitriol, tacalcitol, and calcipotriol ointments achieved complete clearance of scalp psoriasis in 45%, 35.2%, and 17.6% of patients, respectively, with minimal side effects.

In this study, topical calcipotriol was found to be more effective than oral vitamin D for improving mild to moderate alopecia areata, with a 68% improvement rate and no correlation between serum vitamin D levels and treatment efficacy.

In this case study, a 29-year-old male with severe atopic dermatitis and alopecia universalis experienced an excellent response to treatment with upadacitinib, indicating it may be a promising option for similar patients.

This article discusses recent advancements in treatments for psoriasis, including new drug approvals and innovative therapeutic approaches, but reports no new clinical results.

This report describes a 7-year-old girl with monilethrix who showed significant improvement while on acitretin treatment, but symptoms returned after stopping the medication.

This study found that while no predictive factors for response to vismodegib were identified, longer treatment duration was associated with a lower risk of relapse in basal cell carcinoma patients.

This study found that the TYK2 inhibitor deucravacitinib did not significantly improve hair regrowth in patients with alopecia areata compared to placebo, suggesting it may not be effective for this condition. No new safety issues were identified.

In this study, baricitinib, a JAK inhibitor, was found to significantly improve scalp hair regrowth in both adults and adolescents with severe alopecia areata, with many achieving nearly full regrowth by weeks 36 or 52.

This case study presented by the researchers describes the effective use of topical calcipotriene ointment in treating a 6-year-old girl with en coup de sabre scleroderma, resulting in normalization of the sclerotic skin, hair regrowth, and improved pigmentation.

In this randomized study, ViviScal® significantly outperformed a fish extract in increasing non-vellus hair count and achieving clinical and histological improvement in young males with hereditary androgenic alopecia.

This study found that tofacitinib was well tolerated and led to clinical improvement in 77% of potential responders with severe alopecia areata, alopecia totalis, or alopecia universalis.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.